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Several vaccines against SARS-CoV-2 have been licensed and 
are currently being used in the global pandemic. These include 
messenger RNA-based vaccines (viz, Pfizer-BioNTech and Moderna) 
and recombinant adenoviral vector vaccines (viz, AstraZeneca 
and Johnson & Johnson/Janssen). There have recently been safety 
concerns regarding an increased risk of vaccine-induced immune 
thrombotic thrombocytopenia (VITT) following administration of 
the two adenoviral vector vaccines.[1]
The clinical picture of VITT, also referred to as vaccine-induced 
prothrombotic immune thrombocytopenia (VIPIT), is that of a 
moderate to severe thrombocytopenia with thrombotic complications, 
particularly at unusual sites, including cerebral sinus vein thrombosis 
and splanchnic vein thrombosis.[2] The onset is usually 4 - 16 days 
after vaccination. The proposed mechanism, which forms the basis 
for the following recommendations, is similar to that of heparin-
induced thrombocytopenia with thrombosis (HITT). The immune 
response is triggered by the culprit vaccine and not heparin (heparin 
independent).[2,3]
This is a newly described syndrome. It should be differentiated 
from thrombosis associated with established venous risk factors.
Recommendations in this guideline are extrapolated from the 
management of HITT, and reflect current best practice (Table 1).[1,4,5] 
The guidance statements provided here will be updated on availa-
bility of new evidence.
Clinical presentation of VITT
The following side-effects that persist or recur >4 days after 
vaccination should raise clinical suspicion of VITT: 
• new and unusual neurological symptoms, such as severe and/
or persistent headache, blurred vision, seizures and/or focal 
neurological symptoms
• symptoms or signs of thrombosis, such as persistent severe 
abdominal pain, shortness of breath, chest pain, leg pain or swelling.
Diagnosis of VITT
The initial recommended investigation is a full blood count with 
determination of platelet count and a peripheral blood smear 
for review of pseudo-thrombocytopenia and other causes of 
thrombocytopenia.
A diagnosis of VITT should only be considered in a patient with a 
platelet count <150 × 109/L, or a decrease in the platelet count of 50%, 
in the presence of symptoms 4 - 16 days after COVID-19 vaccination 
with adenoviral vector vaccines, namely AstraZeneca and Johnson & 
Johnson/Janssen.
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The ‘4 Ts’ score of HITT has been adapted to establish the pretest 
probability (Table 2).[5,6] An intermediate or high 4 Ts score is 
indicative of the diagnosis of VITT. If the 4 Ts score is low, treatment 
for VITT is not indicated, as the associated risk of VITT is low. Any 
change in clinical or laboratory findings warrants re-evaluation.
Further suggested laboratory investigations include D-dimers 
and fibrinogen. Raised D-dimers (>0.25 mg/L) and low fibrinogen 
(<2 g/L) are suggestive of the diagnosis of VITT.[4] Diagnostic 
assays can be performed if immediately available in patients with an 
intermediate or high 4 Ts score.
These assays include antibodies to platelet factor 4 (PF4), as 
detected by commercial PF4/heparin enzyme-linked immunoassays 
or functional heparin-induced platelet activation assays. A 
presumptive diagnosis of VITT should not be delayed while awaiting 
results of HITT antibody testing. Furthermore, at this time it is 
unknown whether a positive result correlates with thrombotic risk.
Radiology imaging may be appropriate depending on the site of 
the suspected thrombosis: cerebral magnetic resonance venography, 
computed tomography angiography of the chest/abdomen, and 
compression ultrasound of the limbs.
Other important causes of thrombocytopenia that should be 
considered include malaria, HIV or immune thrombocytopenia.
In patients with thrombocytopenia and thrombosis, the following 
differential diagnoses should be considered: 




• systemic lupus erythematosus and/or antiphospholipid syndrome
• paroxysmal nocturnal haemoglobinuria
• sickle cell anaemia.
Management principles of VITT
The treatment principles are similar to severe HITT.[5]
Treatment of suspected or confirmed VITT requires urgent 
consultation with a clinical haematologist or facility with expertise 
in thrombosis. 
• Platelet transfusions must be avoided.
• Anticoagulation with heparins (including heparin flushes) should 
be avoided.
• Warfarin should be avoided in the acute period.
• Treatment with high-dose intravenous immunoglobulin (1 g/
kg daily for 2 days) has been recommended.[7] However, its 
limited availability together with limited data preclude its routine 
recommended use.
• The platelet count should be closely monitored. Platelet recovery is 
defined as a platelet count >150 × 10⁹/L.
• In the setting of vaccines requiring a second dose, the culprit 
vaccine should not be re-administered.[4]
First-line anticoagulants according to the clinical picture include 
direct oral anticoagulants (e.g. rivaroxaban, apixaban, dabigatran) or 
fondaparinux. Most experience in HITT is with rivaroxaban.[8]
Monitoring of peak anti-Xa activity is advised. Samples must be 
drawn 3 hours after the last anticoagulant dose and repeated until 
a therapeutic anti-Xa level is achieved. Once therapeutic levels are 
achieved, continued regular monitoring and dose adjustments are 
recommended. 
• Recommended rivaroxaban dose: 15 mg twice per day for 3 weeks 
followed by 20 mg once per day (reported target anti-Xa activity 
189 - 419 ng/mL)
• Recommended fondaparinux dose: <50 kg: 5 mg sc once per day; 
50 - 100 kg: 7.5 mg sc once per day; >100 kg: 10 mg sc once per day 
(reported target anti-Xa activity 1.20 - 1.26 mg/L).
Initial and periodic assessment of renal function is recommended. 
The dose of these anticoagulants should be adjusted in individuals 
with renal dysfunction (creatinine clearance 30 - 50 mL/min).
Anticoagulation should be continued for at least 3 months.[9]
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Table 1. Key recommendations
• VITT is an extremely rare but potentially fatal complication of 
vaccination with adenoviral vector vaccines
• It is important to consider this complication, because 
management differs from other thrombotic events and standard 
treatment may worsen outcome
• Thrombosis with thrombocytopenia 4 - 16 days post vaccination 
should prompt clinicians to consider the entity
• Thrombocytopenia post vaccination may be due to many other 
reasons in the absence of thrombosis, such as malaria, HIV or 
immune thrombocytopenia 
• Patients with VITT should not be given heparin, platelet 
transfusions or warfarin (acutely)
VITT = vaccine-induced immune thrombotic thrombocytopenia.
Table 2. 4 Ts score evaluating the pretest probability of VITT
Variable Score
Thrombocytopenia
Platelet count fall >50% 2
Platelet count fall 30 - 50% 1
Platelet count fall <30% 0
Timing of onset
Within 4 - 16 days of vaccination 2
>2 weeks of vaccination or unclear exposure 1
No history of vaccination 0
Thrombosis
New thrombosis post vaccination 2
Progressive or recurrent thrombosis 1
No thrombosis 0





0 - 3 indicates low probability
4 - 5 indicates intermediate probability
6 - 8 indicates high probability
VITT = vaccine-induced immune thrombotic thrombocytopenia.
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